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The role of hyperparathyroidism, erythropoietin therapy, and
CMV infection in the failure of arteriovenous fistula in hemo-
dialysis.
Background. Vascular access failure is the main cause of mor-
bidity in hemodialysis. Venous stenosis and subsequent throm-
bosis, as the result of intimal hyperplasia, is the major cause of
vascular access failure. Intimal hyperplasia of the arteriovenous
fistula (AVF) closely resembles the main histopathologic fea-
ture of atherosclerosis. In addition to the classic atherogenic
risk factors, recently, cytomegalovirus (CMV) infection and
parathyroid hormone (PTH) have been suggested as a potential
cause of vascular disease.
Methods. In the present study, we evaluated the relation-
ship between AVF dysfunction and mean plasma PTH, choles-
terolemia, high titer anti-CMV immunoglobulin G (IgG) (250
U/mL), hematocrit, and mean erythropoietin (EPO) dose in
36 cases and 51 controls matched for age, time on dialysis, and
type of AVF.
Results. A higher percentage of patients with AVF failure
had a smoking habit and presented high anti-CMV IgG titer.
Patients with AVF failure had significantly higher mean plasma
PTH, whereas the groups did not differ for mean cholesterol-
emia and hematocrit. Mean EPO dose was slightly, but signifi-
cantly, higher in the AVF failure group. Multiple logistic re-
gression revealed that smoking, EPO dose, elevated mean
plasma PTH and high titer anti-CMV antibodies, significantly
increased the risk of AVF dysfunction.
Conclusion. Our data suggest that hyperparathyroidism,
smoking habits, CMV infection and EPO, independently of
the hematocrit achieved, represent independent risk factors
for hemodialysis access thrombosis.
Vascular access dysfunction is the main cause of mor-
bidity and hospitalization in the hemodialysis popula-
tion, representing most of the yearly cost for each dia-
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lysed patient [1, 2]. Although the economic and clinical
relevance of this condition is well established, its patho-
genesis is still largely unclear [2]. Therefore, the identifi-
cation of relevant risk factors for vascular access failure
would be clinically valuable.
Thrombosis, the leading cause for arteriovenous fistula
(AVF) failure, is usually secondary to stenotic lesions in
the venous outflow system due to an abnormal venous
intima hyperplasia [1, 3]. Histologically, the intima hy-
perplasia observed in the stenotic fistula and in the classic
atheroma are virtually identical, both characterized by
smooth muscle cell migration and proliferation and ex-
tracellular matrix deposition [3, 4]. Thus, it is conceivable
that the two histopathologic pictures are the results of
the same pathogenic mechanisms.
In addition to the classic atherogenic risk factors, in-
cluding smoking and dyslipidemia, several other condi-
tions have recently been suggested to play a role in the
development of atherosclerotic lesions [5]. In the last
10 years, an increasing body of evidence supported an
infectious cause of vascular lesions. A variety of viruses
and bacteria have been suggested as the etiologic agent
for atherosclerosis [6]. Several clinical investigations in-
dicated a possible role of cytomegalovirus (CMV) infec-
tion in the pathogenesis of vascular diseases [6, 7].
Dialysis patients often present an accelerated form of
atherosclerosis. Parathyroid hormone (PTH) has been
shown to influence vascular endothelial and smooth mus-
cle cells growth and function in both experimental mod-
els and in human subjects [8, 9].
Recombinant erythropoietin (EPO) is widely used to
treat anemia in hemodialysis patients, although different
side effects, including hypertension and thrombosis, have
been reported [10]. On the basis of its prothrombotic ef-
fect, EPO therapy has been suggested as a potential cause
for access dysfunction [11]. However, Marchi et al [12]
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did not confirm this hypothesis in a 3-year prospective
study.
Thus, the aim of the present study was to investigate
in a homogeneous hemodialysis population the potential
links between the above-mentioned atherosclerotic risk
factors, the use of EPO and native AVF stenosis and
thrombosis.
METHODS
Study design
The influence of hyperparathyroidism, CMV infec-
tion, and EPO dose on the occurrence of AVF failure
was evaluated retrospectively in a case-control study.
Vascular access patency was routinely monitored by ve-
nous dialysis pressure and urea recirculation and, when
indicated, Doppler ultrasonography. Episodes of AVF
failure, defined as the need for declotting and/or surgery,
were registered throughout an observational period of
5 years (1994 to 1999). Thirty-six patients presented at
least one episode of AVF failure. In all cases, a stenotic
lesion of the venous limb of AVF was identified as the
primary cause of access failure by Doppler ultrasonogra-
phy and was confirmed during surgical revision. Fifty-
one controls were selected in a population of 160 patients
dialyzed in our centers (Bari e Barletta), matching the
cases for age, time on dialysis, and type of vascular access.
Both cases and controls had a native brachiocephalic
AVF as their primary vascular access. All patients were
undergoing chronic bicarbonate hemodialysis for a mean
time of 4.0 hours, three times a week. Blood flow rate
ranged between 250 and 300 mL/min, whereas a dialysate
flow rate of 500 mL/min was routinely used. Kt/V was eval-
uated monthly as a marker of dialysis efficiency. None
of the patients had clinical evidence of malignancy or
procoagulant conditions or took immunosuppressive
medication during the period of observation.
All the laboratory data were collected for both cases
and controls throughout the period of observation (1994
to 1999) or for at least 1 year before the event.
Cardiovascular risk factors such as diabetes melli-
tus, hypertension, and smoking habits were ascertained
through personal interview. In particular, study partici-
pants were classified as a smoker (if they were smoking
before and/or during the observation period) or as a non-
smoker (if they had never smoked). Finally, hyperten-
sion was defined as blood pressure levels higher than
140/90 mm Hg and/or the regular use of at least one
antihypertensive agent.
The EPO weekly dose was obtained by medical record
review. The target hematocrit levels were 32% to 34%
for all our hemodialysis patients.
Table 1. Main clinical features of patients with or without
arteriovenous fistula (AVF) failure
With failure Without failure
No. of cases 36 51
Gender M/F 20/16 30/21
Age years 62.615.1 60.215.2
Time on dialysis months 72.161.2 69.667.2
Kt/V 1.420.1 1.460.2
Diabetes number 5 6
Hypertension number 22 41
Plasma cholesterol 17140 16746
Smoking habit number 18a 13
Anti-CMV IgG 250 U/mL 22b 19
Hematocrit % 31.10.6 30.60.4
EPO weekly dose 5643730c 4111419
PTH pg/mL 62488 30541d
Abbreviations are: CMV, cytomegalovirus; EPO, erythropoietin; PTH, para-
thyroid hormone.
a2 10.8, P  0.001
b2 9.4, P  0.002
c P  0.05 vs. without failure
d P  0.001 vs. without failure
The main clinical data of the patients included in the
study are summarized in Table 1.
Laboratory data
Serum intact PTH plasma concentration was evaluated
in uremic patients using a commercially available two-
sided immunoradiometric assay (IRMA) (Nichols Insti-
tute Diagnostic, San Juan Capistrano, CA, USA) every
3 months throughout the period of observation. Hemato-
crit and serum cholesterol levels were studied monthly by
standard laboratory methods. C-reactive protein (CRP)
was evaluated by nephelometry every 3 months. Anti-
CMV–specific immunoglobulin G (IgG) levels were eval-
uated yearly, as required by the local transplant waiting
list, by an automated microparticle capture immunoenzy-
matic assay (MEIA) (Abbott Park, IL, USA). In this assay,
levels higher than 15 U/mL can be considered positive
for a previous CMV infection and are present in almost
90% of the general population, whereas IgG levels higher
than 250 U/ml are present only in 17% of normal subjects
in our local community and are highly suggestive of a re-
cent and/or active infection. Thus, for the purpose of the
present investigation, we set a priori an arbitrary cutoff
IgG level of 250 U/mL according to previous studies [7].
The mean values of PTH, EPO weekly dose, hemato-
crit, and cholesterol were calculated for each patient
over the whole period of observation. Laboratory data
in the patients with at least one episode of AVF failure
were collected until this event.
Statistical analysis
Data are expressed as mean  standard error of the
mean (SEM). Quantitative data were compared by t test.
Qualitative variables were compared by chi-square. To
identify the variables independently associated with vas-
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cular access failure, the univariate analysis was carried
out comparing patients with and without vascular access
dysfunction. A multivariate logistic regression model
was, then, fit in a forward fashion with the variables
that presented a significant unadjusted difference in the
univariate analysis (P  0.10). Variables were retained
in the model if P  0.05 by the Wald test. Odds ratio
(OR) were calculated from the regression coefficients as
an approximation of the relative risk. Hosmer-Leme-
show’s test was used to calculate the discrimination power
and goodness of fit of the logistic model. Differences
were considered to be significant when P  0.05. The
statistical analysis was performed using the software Stat-
view 5.0 (SAS Institute, Cary, NC, USA).
RESULTS
The main clinical features of the two groups of pa-
tients, with and without AVF failure, are summarized
in Table 1. Age, gender distribution, time on dialysis,
dialysis efficiency, and incidence of diabetes and hyper-
tension were not significantly different between the two
groups. No significant differences were observed for
CRP (with AVF failure, 0.8  0.3; without AVF failure,
0.6  0.2; P  0.3) and serum albumin levels (data not
shown).
We first investigated the presence of classic and novel
risk factors for vascular disease in our patient population
to elucidate their potential influence on AVF patency.
Hypercholesterolemia and smoking habit are two well-
known factors for atherosclerosis. However, mean cho-
lesterol plasma level did not differ significantly between
the patients with and without AVF failure (Table 1). On
the other hand, the number of patients with a docu-
mented smoking habit was markedly higher in the group
with at least one episode of AVF dysfunction (Table 1).
An increasing body of evidence supports the viral hy-
pothesis in the pathogenesis of atherosclerosis, with
CMV as one of the main candidates. Indeed, as pre-
viously observed in patients with severe atherosclerotic
lesions, the incidence of elevated anti-CMV IgG levels
(250 U/mL) was significantly higher in the dialysis pa-
tients who presented at least one episode of AVF failure
(Table 1). In addition, the mean of anti-IgG titer was
strikingly higher in the group of patients with AVF fail-
ure (654  87 U/mL) than in those without (145  20
U/mL, P  0.001).
Mean hematocrit levels were not significantly different
between the two groups (Table 1). On the other hand,
mean EPO weekly dose was significantly higher in the
group of patients with AVF failure (Table 1). No dif-
ferences were observed between the groups for serum
iron, ferritin, and transferrin saturation (TSAT) (data
not shown).
Several studies suggested the involvement of PTH,
Table 2. Multiple logistic regression model for vascular
access thrombosis
OR 95% CI P value
Smoking 10.12 2.4–42.8 0.0017
Anti-CMV IgG 250 U/mL 4.76 1.2–18.8 0.027
Mean EPO dosea 1.43 1.06–1.95 0.029
PTHa 1.34 1.10–1.49 0.0028
Abbreviations are: CMV, cytomegalovirus; EPO, erythropoietin; PTH, para-
thyroid hormone.
a EPO, 1000 IU/week increase; PTH, 100 pg/mL increase
directly or through the calcium/phosphorus levels, in the
development of atherosclerotic lesions in patients with
end-stage renal disease (ESRD) [8]. Thus, we investi-
gated the potential association between PTH plasma lev-
els and the incidence of AVF failure. Interestingly, the
patients with at least one episode of AVF dysfunction
had mean PTH plasma concentration significantly higher
than the ones with no AVF dysfunction during the study
period (Table 1).
To identify the variables independently associated
with vascular access failure, we applied a multiple logistic
regression model to the collected data. In the model
were included four independent variables (EPO dose,
PTH, CMV titers, and smoking). The logistic model clas-
sified correctly 80.4% of patients, and goodness of fit also
was adequate for all of the risk categories. A statistically
significant association with increased risk of AVF dys-
function was observed for smoking habit, EPO weekly
dose and PTH levels, and high levels of anti-CMV IgG
(Table 2). In particular, any increase of 100 pg/mL of
PTH plasma levels was associated with a 30% increase
in the risk of vascular access thrombosis (Table 2). Inter-
estingly, the inclusion of hematocrit in the analysis did
not change the significant association of AVF dysfunc-
tion with EPO dose.
DISCUSSION
The results of this case-control study would strongly
suggest the relevance of some, but not all, atherosclerotic
risk factors in the pathogenesis of hemodialysis AVF
failure and their potential clinical relevance in the identi-
fication of high-risk patients. This observation further
supports the hypothesis that atherosclerotic lesions and
venous stenosis in the AVF would share one or more
pathogenic mechanism(s).
Among the several atherogenic risk factors consid-
ered, smoking habit, high levels of anti-CMV IgG, EPO
dose, and increased plasma levels of PTH were signifi-
cantly and independently associated with an increased
incidence of native fistula thrombosis.
The effects of smoking on vascular wall are well-estab-
lished [13]. It is undoubted that several substances re-
leased systemically by cigarette smoking may influence
a variety of endothelial cell functions [14]. Noteworthy,
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long-term smoking may impair the anticoagulant proper-
ties of endothelial cells and reduce their fibrinolytic ac-
tivity [14]. The direct consequence of such effects may
significantly raise the thrombotic risk. In addition, the re-
duced fibrinolytic activity may play a key role in the
deposition of extracellular matrix components within the
hyperplastic intima. Indeed, plasmin can catalyze the
degradation of fibrin as well as several extracellular ma-
trix components, directly or through the activation of
metalloproteases [14]. On the other hand, there is an
increasing body of evidence suggesting that cigarette
smoking may modulate the endothelium-dependent va-
sorelaxation, inducing a significant alteration in the nitric
oxide synthesis and release [15]. Reduced nitric oxide
may not only increase vascular smooth muscle cells con-
traction, but also their proliferation and migration, one
of the main features of intima hyperplasia both in the
atherosclerotic lesion and in the venous stenosis of the
native fistula. Finally, cigarette smoking may induce an
increased production of advanced glycation end products
(AGEs) [16]. AGEs are well known mediators of endo-
thelial cell dysfunction and smooth muscle cell prolifera-
tion both in vivo and in vitro. Therefore, cigarette smok-
ing may directly and/or indirectly influence both the
development of the stenotic lesion and the thrombotic
events in the native AVF.
Other well-established atherogenic factors, such as hy-
percholesterolemia, hypertension, and diabetes, did not
influence, in our patient population, the risk for AVF
failure. Deposition of lipid droplets as well as the pres-
ence of foam cells within the hyperplastic intima are key
features of the atherosclerotic lesions [4], but not of
venous stenosis of the failing AVF. Thus, it is not surpris-
ing that we do not observe any association between ele-
vated cholesterol level and AVF. On the other hand, it
should be considered that cholesterol level in our patient
population was within the normal range. Thus, we cannot
definitively exclude dyslipidemia as a risk factor. The
diabetic milieu is a powerful fibrogenic stimulus and in-
duces, directly or through the formation of AGEs, a
variety of micro- and macrovascular damage. Although
theoretically diabetes can play a key role in AVF pathol-
ogy, we could not demonstrate any significant association
between diabetes and AVF dysfunction. However, the
low incidence of this metabolic disease among our pa-
tients biased the results obtained and would warrant
further studies to define its role in the pathogenesis of
AVF failure.
In the last 10 years, an increasing body of evidence
supported the viral hypothesis for the pathogenesis of
atherosclerosis [5]. In particular, CMV infection has
been suggested as the culprit for the development of
atherosclerotic lesions. This hypothesis was first based
in 1987 on the observation of a strong association be-
tween the presence of high titer anti-CMV antibodies
and atherosclerotic lesions [7]. Several studies demon-
strated, by polymerase chain reaction (PCR), in situ hy-
bridization and immunohistochemistry, the presence of
CMV directly within the atherosclerotic lesions [5]. Al-
though the role of CMV in vascular diseases seems estab-
lished, its mechanisms of action are still largely unclear.
Recently, several authors have demonstrated that CMV
genome includes a gene that encodes for a chemokine
[17]. Once secreted, this peptide can recruit leukocytes
in the site of infection. This event, on one hand, would
give the virus a chance to spread, infecting the infiltrating
cells, and, on the other hand, could initiate a proinflam-
matory cascade within the vessel wall, eventually leading
to intimal hyperplasia. Other viruses and/or bacteria
have also been suggested as etiologic factors in the “in-
flammatory” process underlying the atherosclerotic le-
sion. A possible role for the intracellular pathogen Chla-
mydia pneumoniae has been supported by several studies
[5]. Chlamydia, indeed, can infect endothelial cells and
cause their activation, inducing the expression of chemo-
kines, adhesion molecules, and tissue factor [5]. How-
ever, in our patient population, we did not observe any
significant difference in the presence and/or the title of
specific anti-chlamydia IgG (data not shown).
This is the first study reporting a significant association
between the detection of high titer anti-CMV antibodies
and AVF dysfunction. Interestingly, this observation
stands true also when other variables are taken into
consideration, suggesting high titer anti-CMV antibody
as an independent risk factor. The cutoff levels used are
close to those selected by Adam et al [6] in their original
report, even if the patients enrolled in our study are
immunodepressed. Nevertheless, our observation only
indirectly suggests a cause-effect relationship between
CMV and AVF dysfunction. Indeed, further clinical pro-
spective studies using larger patients population and his-
tologic investigations, looking for CMV within the vessel
wall of the failed fistula, are warranted to definitively
address this issue.
The relationship between the secondary hyperpara-
thyroidism of hemodialysed patients and the accelerated
atherosclerosis, often observed in this patient popula-
tion, has been suggested by several authors, based mainly
on clinical observations [8]. Indeed, the progression of
atherosclerotic lesions is significantly slowed down in
hemodialysis patients undergoing parathyroidectomy
[8]. This hypothesis is now supported by an increasing
number of studies reporting the presence of specific PTH
receptors on endothelial and smooth muscle cell surface
[9]. Although the hypothesis of a direct effect of PTH
on the vessel wall is intriguing, we cannot rule out the
possibility that hyperparathyroidism may participate in
the pathogenesis of AVF stenosis as well as atheroscle-
rotic lesions through an increased calcium-phosphorus
product, as suggested by several authors [8]. Indeed,
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microcalcification are often observed within the athero-
mas [8]. Although we do not have any description of such
a phenomenon in the AVF, we can assume its presence in
the failing AVF as well. Finally, patients with high PTH
are surely more exposed to high doses of vitamin D.
Recently, vitamin D has been suggested as a potential
atherogenic factor based on its effect on vascular smooth
muscle cells as well as lipid metabolism [8].
The role of hematocrit and EPO therapy in the patho-
genesis of AVF thrombosis is controversial. In the
United States phase III multicenter trial, hematocrit in
the treated patients increased from 22% to 32% to 38%
on EPO therapy and, in this group, the rate of AVF
thrombosis was lower than the one observed in a large
cohort of patients who did not receive EPO [10]. How-
ever, similar increases in hematocrit through the use of
EPO in the Canadian multicenter trial showed a trend,
although not statistically significant, toward increased
access thrombosis [11]. The reason for this higher rate of
AVF failure is unclear since no correlation was observed
with the level of hematocrit. Our study confirms this
observation in a relatively small, but homogeneous group
of dialysis patients. Indeed, in the multivariate analysis,
although the EPO weekly dose was significantly corre-
lated with the AVF failure, no such correlation could
be observed for the hematocrit. This finding strongly
supports the hypothesis of a direct vascular effect of EPO
in the pathogenesis of AVF stenosis. Indeed, recently,
Ikegaya et al [18] reported a striking increase of EPO
receptor expression in the stenotic and failing fistula. On
the other hand, we must consider that a higher EPO
dose to obtain the same hematocrit target may reflect
an inflammatory state. Indeed, our cases presented with
a CRP slightly, but significantly, higher than the controls
(data not shown).
CONCLUSION
Based on our data, hyperparathyroidism, smoking
habit, high titer anti-CMV IgG, and EPO dose might
represent four valuable clinical markers to identify pa-
tients at high risk for AVF dysfunction. Further studies
are warranted to define whether the modification of
these parameters may lead to a reduced incidence of
fistula thrombosis in hemodialysis. Indeed, although the
incidence of native AVF failure is 0.1 failure/patient/
year, there are several patients with recurrent episodes
of AVF dysfunction and the definition of risk factors
may help to identify in early phases these patients and
eventually prevent further episodes of failure in this par-
ticular population of hemodialysis patients.
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